GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop
tumor cells from dividing so they stop growing or die. GTI-2040 may help docetaxel kill more
tumor cells by making them more sensitive to the drug.
PURPOSE: This phase II trial is studying how well giving GTI-2040 together with docetaxel and
prednisone works in treating patients with prostate cancer that has not responded to hormone
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Princess Margaret Hospital, Canada University Health Network, Toronto